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Polymorphous low-grade adenocarcinoma (PLGA) is the second most frequent type of malignant tumor of the minor salivary 
glands. We identified PRKD1 hotspot mutations encoding p.Glu710Asp in 72.9% of PLGAs but not in other salivary gland 
tumors. Functional studies demonstrated that this kinase-activating alteration likely constitutes a driver of PLGA. 
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PLGA is the second most common intraoral malignant salivary gland tumor, preferentially affecting 
the minor salivary glands1. This tumor occasionally originates in other anatomical sites, including 
the lungs and breast2. PLGAs are characterized by cytological uniformity and histological 
diversity1. Despite their infiltrative growth pattern and tendency for perineural invasion, PLGAs 
have a relatively indolent clinical course, with lymph node metastasis in up to 29% of cases and  
 rare distant metastasis3,4. Owing to the large spectrum of histological appearances of PLGAs, the 
differentiation of these tumors from more aggressive forms of salivary gland cancer is challenging, 
especially in small diagnostic specimens. 
Recent studies have demonstrated that distinct types of malignant salivary gland tumors, including 
adenoid cystic carcinoma (AdCC), mucoepidermoid carcinoma and secretory carcinoma, are driven 
by specific highly recurrent somatic genetic alterations (for example, fusion genes)5. Like PLGA, 
these tumor types can also originate in other anatomical sites, including the lungs and breast2. We 
therefore reasoned that PLGA might be driven by a highly recurrent somatic genetic alteration. 
To test this hypothesis, we subjected three consecutive PLGAs to massively parallel RNA 
sequencing and whole-exome sequencing and a separate set of three PLGAs to whole-exome 
sequencing (Supplementary Table 1). RNA sequencing did not identify any recurrent in-frame 
fusion genes (Supplementary Table 2). By contrast, whole-exome sequencing identified two 
somatic heterozygous single-nucleotide variants (SNVs) in the PRKD1 gene, c.2130A>T and 
c.2130A>C, affecting a highly conserved amino acid in the catalytic loop (Fig. 1a) and resulting in 
the same amino acid substitution, p.Glu710Asp, in five of six cases (Fig. 1b, Supplementary Fig. 1 
and Supplementary Table 1). RNA sequencing demonstrated that the mutant alleles were 
expressed (Supplementary Fig. 2 and Supplementary Table 1). No additional recurrent somatic 
SNVs or insertion-deletions (indels) were detected (Supplementary Table 3). We therefore 
subjected a validation cohort of 53 PLGAs to Sanger sequencing and targeted amplicon sequencing 
of PRKD1 exon 15 and confirmed the presence of the somatic c.2130A>T and c.2130A>C 
mutations in 41.5% and 30.2% of PLGAs, respectively (Fig. 1b, Supplementary Fig. 3 and 
Supplementary Table 4). In total, 43 of 59 (72.9%) PLGAs tested harbored a PRKD1 mutation 
encoding p.Glu710Asp. Detailed pathological analysis of PLGAs with mutated and wild-type 
PRKD1, however, did not identify distinct histological features that would differentiate the two 
groups (data not shown). PLGAs with and without the PRKD1 mutation encoding p.Glu710Asp 
were found to express PRKD1 protein (Fig. 1c and Supplementary Fig. 2b,c), suggesting that, as 
with other mutation-activated oncogenes6, the expression of PRKD1 protein is more pervasive than 
the presence of a PRKD1 hotspot mutation. 
PRKD1 is a serine-threonine kinase that has a role in cell adhesion, cell migration, vesicle transport 
and cell survival7. We found that the PRKD1 gene was mutated in 2.2% of the cancer samples 
included in The Cancer Genome Atlas (TCGA) and other published data sets available on 
cBioPortal8, but none of these cancers harbored the PRKD1 c.2130A>T or c.2130A>C 
(p.Glu710Asp) mutations, suggesting that these SNVs might be unique to PLGA (Fig. 1d,e). In 
addition, these new PRKD1 mutations have not been reported in the Catalog of Somatic Mutations 
in Cancer9 (COSMIC, v68; data not shown). To determine whether the PRKD1 mutations encoding 
p.Glu710Asp would be pathognomonic for PLGA, we investigated the presence of these mutations 
in a series of 311 tumors of the salivary glands (186 malignant and 125 benign lesions), of which 12 
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were PLGAs. The PRKD1 mutations encoding p.Glu710Asp were found in eight of the PLGAs but 
not in any of the other salivary gland tumors studied (Fig. 1f and Supplementary Table 5). 
Therefore, our findings demonstrate that the PRKD1 hotspot mutations encoding p.Glu710Asp, 
akin to the CRTC1-MAML2 and MYB-NFIB fusion genes defining subsets of mucoepidermoid 
carcinoma and AdCC, respectively5, define a subset of PLGAs of the salivary glands and might be 
useful as an ancillary diagnostic marker to differentiate PLGAs from other forms of salivary gland 
tumors. In addition, the presence of a PRKD1 mutation encoding p.Glu710Asp was significantly 
associated with the metastasis-free survival of individuals with malignant salivary gland tumors (P 
= 0.027; Fig. 1g, Supplementary Table 6 and Supplementary Note), suggesting that these 
mutations might be useful in the molecular prognostic work-up of salivary gland cancers. 
The p.Glu710Asp hotspot alteration affects the catalytic loop HCDLKPEN of the PRKD1 protein 
kinase domain (Fig. 1a) and was predicted to be pathogenic by independent mutation function 
assessment algorithms (Supplementary Table 3). Although the crystal structure of PRKD1 is not 
yet solved, homology modeling suggested that the p.Glu710Asp alteration could either interfere 
with ADP binding by altering coordination with Mg2+ or affect enzyme kinetics, as it is positioned 
in between the ATP donor binding site and the putative proton acceptor (Fig. 2a and 
Supplementary Fig. 4a). The glutamic acid residue is highly conserved among the CAMK kinases; 
however, an aspartic acid residue is frequently observed within the native structures of AGC 
kinases, suggesting that the identified alteration is likely active but might induce a functional shift 
(Supplementary Fig. 4b). Consistent with these protein structure predictions, in a cell-free in vitro 
kinase assay, p.Glu710Asp-mutant PRKD1 displayed significantly increased transphosphorylation 
of the serine-threonine substrate CREBtide and elevated autocatalytic activity in comparison to 
wild-type PRKD1 (P < 0.0001; Fig. 2b and Supplementary Fig. 5a). Forced expression of wild-
type and p.Glu710Asp-mutant PRKD1 in embryonic kidney epithelial and non-malignant breast 
epithelial cell lines (Supplementary Fig. 5b) resulted in increased phosphorylation of 
Ser738/Ser742 within the activation loop and Ser910 in the autocatalytic site of the mutant PRKD1 
protein relative to wild-type protein in all subcellular compartments (Fig. 2c and Supplementary 
Fig. 5c), in agreement with the higher trans- and autocatalytic kinase activity detected in the cell-
free kinase assay. 
Previous studies have suggested that PRKD1 activation reduces cell migration and invasion but 
promotes the growth of epithelial cells7. Consistent with this notion, forced expression of 
p.Glu710Asp-mutant PRKD1 in conventional in vitro models resulted in reduced cell migration, 
despite an increase in cell viability (Supplementary Fig. 6). To ascertain whether the PRKD1 
hotspot mutations encoding p.Glu710Asp would affect the growth and glandular architecture of 
epithelial cells, we forced expression of wild-type and p.Glu710Asp-mutant PRKD1 in two non-
malignant breast epithelial cell lines, MCF10A and MCF12A, grown in three-dimensional 
cultures10. These cells were chosen because PLGA cell lines and non-malignant models of minor 
salivary gland cells are not available and because, albeit rarely, primary PLGAs have been reported 
in the breast2. Forced expression of p.Glu710Asp-mutant PRKD1 changed the hollow spheroid, 
acinar-like structures formed by parental or empty vector–transfected MCF10A and MCF12A cells 
into larger, coalescent structures with filled lumens and irregular contours not uncommonly 
displaying infiltrating edges, a phenotype consistent with that induced by the forced expression of 
other oncogenes in this model system10,11 (Fig. 2d). Taken together, our findings demonstrate that 
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the somatic PRKD1 hotspot mutations encoding p.Glu710Asp are likely activating and might confer 
a neoplastic advantage to epithelial cells. 
We have identified somatic PRKD1 activating hotspot mutations encoding p.Glu710Asp in the 
majority of PLGAs, which might be employed as an ancillary molecular marker to differentiate 
PLGA from its more aggressive mimics, including AdCC. PRKD1 emerges as a new cancer-related 
gene, which likely constitutes a driver of PLGA and might be exploited as a diagnostic aid and 
therapeutic target. Our study emphasizes that investigating the genetic underpinnings of rare cancer 
types can lead to the identification of new oncogenic drivers and help in the development of a 
molecular taxonomy of cancers12.  
J.S.R.-F. and C.M. interpreted the immunohistochemical results. C.K.Y.N., K.C.C. and P.C.B. 
performed statistical analyses. B.W. and J.S.R.-F. wrote the first draft of the manuscript, which was 
initially reviewed by I.W., S.P., L.G.M., D.W., L.N., B.P.R. and P.C.B. All authors edited and 
approved the final draft.  
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ONLINE METHODS 
Subjects and samples. After obtaining institutional review board (IRB) approval from the 
respective institutions of the authors, representative histological blocks of PLGAs were retrieved 
from the pathology archives of the respective pathology departments and sent to the pathology 
department of the University Health Network (UHN) (Toronto, Ontario, Canada) or Memorial 
Sloan-Kettering Cancer Center (MSKCC) (New York, New York, USA). In addition, three frozen 
samples of PLGAs and matched adjacent normal salivary gland samples were retrieved from the 
MSKCC Tumor Procurement Service, and three frozen samples of PLGAs were retrieved from the 
UHN Biospecimen Sciences Program. 
Sixty-eight cases were reviewed by the contributing pathologists and centrally reviewed by two 
pathologists with an interest and expertise in head and neck cancer pathology (I.W. and B.P.-O.). 
Only cases classified as classic PLGA according to the World Health Organization definition were 
included in this study1. Cases that fulfilled the diagnostic criteria of cribriform adenocarcinoma of 
the minor salivary glands or adenocarcinoma not otherwise specified were excluded1. In total, 59 
classic PLGAs were included in this study, six of which were fresh frozen and 53 of which were 
formalin fixed and paraffin embedded. Patient consents were obtained if required by the IRB 
protocols approved by each author’s institution. Follow-up data were obtained from patient charts 
from the authors’ institutions. Before tissue processing, samples were anonymized. 
The discovery cohort (Supplementary Table 1) comprised six fresh-frozen PLGAs, three of which 
had matched frozen adjacent normal salivary gland tissue available. These three cases with matched 
adjacent normal tissue were microdissected with a needle under a stereomicroscope as previously 
described13. RNA was extracted from microdissected tumor samples as previously described13 and 
subjected to paired-end massively parallel RNA sequencing. DNA was extracted separately from 
microdissected tumor samples and normal adjacent tissues as previously described13 and subjected 
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to whole-exome sequencing. From the remaining three cases, only representative frozen tumor 
tissues were available; these cases were microdissected and DNA was extracted and subjected to 
whole-exome sequencing. 
The validation cohort (Supplementary Table 4) consisted of representative formalin-fixed, 
paraffin-embedded samples from 53 PLGAs. These samples were microdissected with a needle 
under a stereomicroscope, and DNA was extracted and quantified and its quality assessed as 
previously described13. 
For power calculations, assuming that, akin to other rare tumor types14,15, PLGAs would be driven 
by a recurrent hotspot mutation or fusion gene present in ≥70% of cases, a binomial distribution 
showed that by sequencing six samples we would be able to identify a recurrent event (occurring in 
two or more cases) with >90% statistical power. 
Paired-end massively parallel RNA sequencing and fusion gene identification. The three 
PLGAs retrieved from MSKCC were subjected to massively parallel RNA sequencing using a 
validated protocol16 employed in the MSKCC Integrated Genomics Operation (iGO). In brief, 
paired-end RNA sequencing was performed with 2 × 75-bp cycles on the Illumina HiSeq 2000 
platform. Data were aligned to the reference human genome hg19 using Bowtie 2 (ref. 17). For 
PLGA_1, PLGA_2 and PLGA_3, 121.7, 66.7 and 56.8 million reads were obtained, respectively. 
Read pairs supporting fusion transcripts were identified using ChimeraScan (v0.4.5)18 and deFuse 
(v0.6.1)19. To filter out common alignment artifacts and normal transcriptional variation, we 
removed fusion gene and read-through candidates that were also found in a set of 47 normal 
samples from TCGA (project 4767). Candidate fusions were annotated using Oncofuse20 
(Supplementary Table 2). 
Whole-exome sequencing. For the MSKCC samples, microdissected tumor and germline DNA 
were subjected to exome capture with SureSelect Human All Exon v4 (Agilent Technologies) using 
a validated protocol16,21 employed in the MSKCC iGO. An average of 154 million 75-bp paired-
end reads were generated on an Illumina HiSeq 2000 instrument for each sample, equivalent to an 
average depth of 102× (range of 84.5–181.5×). 
For the UHN samples, DNA from the three tumors was subjected to exome capture with Agilent 
SureSelect All Exon G3362 (203,733 regions; 50,075,646 bp). Each sample was run in a single 
flow cell lane of an Illumina HiSeq 2000 instrument, generating approximately 220 million 101-bp 
paired-end reads, to an average depth of 159× (range of 137–187×). 
Variant calling. For the MSKCC samples, reads were aligned to the reference human genome hg19 
using the Burrows-Wheeler Aligner (BWA, v0.6.2)22. Local realignment and quality score 
recalibration were performed using the Genome Analysis Toolkit (GATK, v3.1.1)23. Deduplication 
was performed using Picard (v1.92). Somatic SNVs were called using MuTect (v.1.1.4)24, and 
small somatic indels were called using VarScan2 (v2.3.6)25 and the GATK HaplotypeCaller 
(v3.1.1)23. Variants found with >5% global minor allele frequency in dbSNP (Build 137) or that 
were supported by <5 reads were disregarded. SNVs for which the tumor variant allele fraction was 
<5 times than that of the normal variant allele fraction were disregarded. All indels were manually 
inspected using the Integrative Genomics Viewer (IGV)26. 
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For the UHN samples, reads were aligned to the UCSC build hg19 reference using Novoalign 
(v2.07.14, Novocraft Technologies). Alignments were optimized by soft clipping low-quality end 
positions and rescuing poorly aligned reads via high-quality anchoring of their fragment pair. 
SAMtools (v1.18)27 was used for deduplication and filtering. Local realignment, quality score 
recalibration and variant detection were performed using GATK (v2.4.7)23, employing 
recommended best practices (v3 and v4). On-target variants (padded by 10 bp) were considered, 
and variants that were flagged by GATK base quality, read depth, alternate allele frequency and 
haplotype inconsistency filters were removed. Variants in dbSNP (Build 137; variants not flagged 
as somatic or clinical or as having a minor allele frequency of <1%; ref. 28) or in the 1000 
Genomes Project (phase 1, release v3, 23 November 2010) were removed. Variants were excluded 
if they occurred in Fuentes29, ENCODE30 or the Duplicated Gene Database31 or in ten normal 
blood samples (data not shown). All COSMIC variants (v64) were white-listed9,32. 
Prediction of the functional effect of the mutations was performed using PolyPhen-2 (ref. 33), 
MutationTaster34, Mutation Assessor35, FATHMM36, CHASM (breast, head and neck, and other 
classifiers)37, CanDrA (breast classifier)38 and CADD39. 
PCR amplification, Sanger sequencing and targeted amplicon sequencing. The presence of 
somatic PRKD1 mutations encoding p.Glu710Asp was validated in all PLGAs from the discovery 
cohort and investigated in all PLGAs from the validation cohort by Sanger sequencing analysis of 
tumor and germline samples as previously described40. For this analysis, primers (Supplementary 
Table 7) to amplify a 338-bp fragment covering exon 15 of the PRKD1 gene (chromosomal 
position: chr. 14: 30,068,073–30,068,410) were designed using OligoPerfect (Life Technologies). 
PCR fragments were then purified using ExoSAP-IT (USB) and sequenced as previously 
described40. 
For targeted amplicon sequencing, 5 ng of genomic DNA was amplified with primers specific for 
exon 15 of the PRKD1 gene (Supplementary Table 7) using a high-fidelity Taq polymerase 
(Roche). PCR amplicons were sequenced on a MiSeq instrument (Illumina) using 150 × 150 
chemistry. Reads were aligned to the reference human genome hg19 using BWA (v0.6.2)22. Local 
realignment and quality score recalibration were performed using GATK (v3.1.1)23. Mutations 
were called using the GATK HaplotypeCaller (v3.1.1)23 and were manually inspected using 
IGV26. 
Immunohistochemistry. Representative sections from 3 frozen PLGAs included in the discovery 
set from MSKCC and from 18 formalin-fixed, paraffin-embedded PLGAs from the validation 
cohort were cut at 4 μm and mounted on Superfrost Plus slides (Fisher Scientific). Frozen sections 
of each of the three tumors were briefly fixed in acetone and subjected to PRKD1 immunohisto-
chemical analysis. Formalin-fixed, paraffin-embedded sections were subjected to heat-induced 
antigen retrieval using the pH 9 Target Retrieval Solution (Dako) at 92.8 °C for 20 min in a water 
bath, and immunohistochemical analysis was then performed using a polyclonal antibody to 
PRKD1 (Sigma-Aldrich, HPA029834; 1:250 dilution). Detection of bound antibody was performed 
using the ABC-diaminobenzidine method (Vector Laboratories). Negative controls (omission of the 
primary antibody and substitution of the primary antibody with IgG-matched control) and positive 
controls (formalin-fixed, paraffin-embedded pellets41 of MCF12A cells transfected with empty 
vector or with vector for wild-type or p.Glu710Asp-mutant PRKD1) were included in each slide 
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run. Sections were analyzed by two pathologists (C.M. and J.S.R.-F.) blinded to the PRKD1 
mutation status of the cases using the H-score system, whereby cytoplasmic expression in 
histologically unequivocal neoplastic cells was semiquantitatively assessed. Nuclear expression was 
semiquantitatively assessed using the Allred scoring system as previously described42; an Allred 
score of >2 was considered positive. Unequivocal membranous expression was not observed in any 
case. No statistically significant difference in the expression levels of cytoplasmic and nuclear 
PRKD1 was observed between PLGAs with mutant and wild-type PRKD1 (Supplementary Fig. 
2c). 
PRKD1 c.2130A>T and c.2130A>C (p.Glu710Asp) mutation screening in salivary gland 
tumors. We retrieved 311 primary salivary gland lesions from the pathology departments of UHN, 
Cleveland Clinic and MSKCC. The inclusion criteria for the cases were as follows. Consecutive 
cases of salivary gland lesions diagnosed and managed at UHN between January 2002 and 
December 2010, at Cleveland Clinic between January 1999 and December 2013, and at MSKCC 
between January 2008 and December 2013 were retrieved from the respective hospital files; referral 
cases and cases where insufficient tumor material was available were excluded (Supplementary 
Table 5). DNA was extracted from all cases as described above. In 96-well plates, the DNA sam-
ples from these cases and 8 randomly selected PLGAs previously included in the validation series 
described above were assembled by 3 of the authors and subjected to Sanger sequencing as 
described above by another author, who was blinded to the identity and diagnosis of the samples 
and prior sequencing results. 
To define the impact of the PRKD1 mutations encoding p.Glu710Asp on the outcome of patients 
with malignant salivary gland tumors, a cohort of malignant salivary gland tumors was 
retrospectively accrued by combining (i) all cases of malignant salivary gland tumors subjected to 
screening for the PRKD1 c.2130A>T and c.2130A>C (p.Glu710Asp) mutations with (ii) all cases 
of PLGA analyzed in this study. This combined data set comprised 237 individual patients. Follow-
up data were obtained from patient charts reviewed by three of the authors. After follow-up data 
were obtained, samples were anonymized. Follow-up information was available for 149 patients 
with malignant salivary gland tumors, ranging from 1 to 180 months (median of 34 months; 
Supplementary Table 6). Metastasis-free survival was expressed as the number of months from 
diagnosis to the occurrence of distant relapse. Survival analysis was performed using SPSS version 
20 (IBM). Cumulative survival probabilities were calculated using the Kaplan-Meier method. 
Differences between metastasis-free survival rates were tested with the log-rank test. A P value of 
<0.05 was considered significant. 
Homology modeling. A homology model of the kinase domain of PRKD1 and p.Glu710Asp-
mutant PRKD1 was generated using SWISS-MODEL43–46 on the structure of CHEK2 (Protein 
Data Bank (PDB) 2YCR) with which it has 40% sequence identity (Supplementary Fig. 4a,b). The 
model for the ADP molecule was obtained from a related CHEK2 structure (2CN5) with overlap 
generated by PyMOl (v1.5.0.4, Schrödinger). The homology models were evaluated using 
QMEAN47–50 (Supplementary Fig. 4a). The QMEANnorm score and QMEAN z score49 
estimate the absolute quality of a homology model in comparison to X-ray crystallography 
reference structures. The reference structures are a non-redundant subset of PDB with less than 30% 
pairwise sequence identity among themselves and resolved at a resolution of <2 Å. PRKD1 models 
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have QMEAN z scores of −1.80 (wild type) and −1.71 (mutant), resulting in a QMEANnorm score 
of 0.60 for both (Supplementary Fig. 4a) and placing the models well within the range of scores 
for similarly sized resolved structures in the reference set. Residue-by-residue examination showed 
that the active site and mutation region (Supplementary Fig. 4a) were modeled with high accuracy. 
Model error was dominated by regions near flexible loops and toward the extremities of the 
homology model. All homology model visualizations are for one chain in the dimer and were 
rendered using the Visual Molecular Dynamics software suite51. 
Sequence alignment and analysis of the PRKD1 mutant site against the human protein kinase 
complement. Multiple-Sequence Comparison by Log Expectation (MUSCLE)52 was used to align 
the mutated kinase domain of PRKD1 against an alignment of the eukaryotic protein kinase (ePK) 
domains used in Manning et al.53 describing the major kinase groups. All sequences observed to 
display a glutamic acid or aspartic acid at the homologous site of the PRKD1 alteration were 
identified and used in conjunction with Kinome-render54 to annotate the tree shown in 
Supplementary Figure 4b. 
Amino acid sequence alignment of PRKD1 across species. The amino acid sequences of the 
PRKD1 protein from Homo sapiens, Mus musculus, Rattus norvegicus, Pan troglodytes, Equus 
ferus caballus, Bos taurus, Gallus gallus, Xenopus tropicalis, Danio rerio and Drosophila 
melanogaster were retrieved from Ensembl and aligned using ClustaW in DNASTAR Lasergene. 
Cell lines. MCF10A, MCF12A, HEK293T and NIH3T3 cells were purchased from the American 
Type Culture Collection (ATCC), authenticated using short tandem repeat profiling as previously 
described40 and tested for mycoplasma using the PCR-based Universal Mycoplasma Detection kit 
(ATCC). All cell lines were maintained in an atmosphere with 5% CO2 at 37 °C. MCF10A and 
MCF12A cells were cultured in DMEM/F12 supplemented with 5% horse serum, 20 ng/ml 
epidermal growth factor (EGF), 10 μg/ml insulin, 0.5 μg/ml hydrocortisone and 1% penicillin-
streptomycin as described in ref. 10, and HEK293T and NIH3T3 cells were cultured in DMEM 
high glucose supplemented with 10% FBS and 1% penicillin-streptomycin. 
Vector construction, mutagenesis, transformation and plasmid preparation. The human 
PRKD1 (NM_002742) cDNA clone was purchased from Origene (RG211676; C-terminal 
TurboGFP tag). The mutation encoding p.Glu710Asp was introduced in pCMV6:PRKD1-tGFP 
using the Q5 Site-Directed Mutagenesis kit (New England BioLabs). The presence of the correct 
mutation and the absence of rearrangements were confirmed by Sanger sequencing (primer 
sequences available in Supplementary Table 7). 
Transfections of mammalian cells and analysis of transgene expression. Transfections with 
plasmids were performed using Lipofectamine LTX and PLUS Reagent (Life Technologies) 
following the manufacturer’s guidelines. The expression of transgenes was visually evaluated 48 h 
after transfection using a Nikon Eclipse Ti fluorescence inverted microscope and by protein blotting 
using antibodies to PRKD1/PKCμ (see below). 
Protein blotting. Standard protein blotting was conducted as previously described40 using 
antibodies against PRKD1/PKCμ (2025), phosphorylated PRKD1/PKCμ (Ser744/Ser748; 2054), 
phosphorylated PRKD1/PKCμ (Ser916; 2051), MEK1/MEK2, AIF, vimentin and histone H3 (Cell 
Fractionation Antibody Sampler kit, 11843; all from Cell Signaling Technology; 1:1,000 dilution). 
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Conjugated IRDye680RD/800CW secondary antibodies were used at a 1:15,000 dilution and 
detected using the Odyssey Infrared Imaging System (LI-COR Biosciences)40. Quantification and 
analysis were performed using LI-COR Image Studio Software. When required, stripping of 
membranes was performed using Restore PLUS Western Blot Stripping Buffer (Thermo Scientific). 
Confocal microscopy of PRKD1 subcellular localization. Cells growing on coverslips expressing 
PRKD1-tGFP, PRKD1(Glu710Asp)-tGFP and tGFP (control) proteins were fixed in 10% buffered 
formalin (Fisher Scientific), washed with PBS, counterstained with 4′,6-diamidino-2-phenylindole 
(DAPI; Life Technologies) and mounted using ProLong Gold Antifade Reagent (Life 
Technologies). Photomicrographs were acquired using a Leica TCS SP5-II Upright microscope. All 
experiments were performed in triplicate. 
Cell fractionation. Protein fractions enriched for cytoplasmic, organellular/membranous and 
nuclear/cytoskeletal components from MCF10A and MCF12A cells expressing the PRKD1-tGFP, 
PRKD1(Glu710Asp)-tGFP and tGFP proteins were prepared using the Cell Fractionation kit (9038; 
Cell Signaling Technology) following the manufacturer’s protocol. The efficiency of separation was 
evaluated using the Cell Fractionation Antibody Sampler kit (11843, Cell Signaling Technology). 
Three-dimensional cell cultures and confocal microcopy. Overlay three-dimensional cultures of 
MCF10A and MCF12A cells expressing the PRKD1-tGFP, PRKD1(Glu710Asp)-tGFP and tGFP 
proteins were carried out as previously described10. At day 14, phase-contrast images of acinar 
structures were acquired (EVOS XL Imaging System, Life Technologies); cells were fixed, stained 
with DAPI, extracted from the three-dimensional cultures and mounted as described in Lee et al.55. 
Confocal images were acquired at the acinar-like spheroid midsection using a Leica TCS SP5-II 
Upright microscope. All experiments were performed in triplicate. 
PRKD1-tGFP and PRKD1(Glu710Asp)-tGFP immunoprecipitation and serine-threonine 
kinase assays. Protein lysates of HEK293T cells were prepared 48 h after transfection. The 
PRKD1-tGFP, PRKD1(Glu710Asp)-tGFP and tGFP proteins were immunoprecipitated using anti-
tGFP(2H8)-conjugated magnetic beads (Origene). All steps were carried out at 4 °C. All 
experiments were performed in triplicate. 
Serine-threonine kinase activity was evaluated using the ADP Hunter HS Assay (DiscoveRx) 
following the procedure recommended by the manufacturer. The immunocomplexes bound to beads 
were resuspended in 40 μl of ADP Assay Buffer supplemented with 25 μM ATP and with 100 μM 
CREBtide as a substrate (KRREILSRRPSYR; Enzo Life Sciences); autophosphorylation was 
evaluated by omitting CREBtide in the reaction. The reactions proceeded for 30 min at 30 °C with 
vigorous agitation, and were terminated by placing the tubes on a magnetic stand and removing the 
supernatant for the ADP detection step. Fluorescence readings (excitation/emission: 530/590 nm) 
were taken after a 20-min incubation using a Victor X4 Multimode Plate Reader (PerkinElmer). 
The immunocomplexes bound to beads were mixed with 2× NuPAGE LDS Sample Buffer (Life 
Technologies) and heated for 5 min at 95 °C, and eluted proteins were resolved by electrophoresis. 
Standard protein blotting, using antibodies against PRKD1/PKCμ and phosphorylated 
PRKD1/PKCμ, was carried out as described above. 
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Growth curves. MCF10A and MCF12A cells expressing PRKD1-tGFP, PRKD1(Glu710Asp)-
tGFP and tGFP were seeded in 96-well plates (1,500 cells/well, in triplicate), and proliferation was 
monitored over 5 d using the CellTiter-Blue Cell Viability Assay (Promega). Fluorescence readings 
were performed using the Victor X4 Multimode Plate Reader (PerkinElmer). Growth curves were 
plotted and analyzed (multiple t tests, corrected for multiple comparisons using the Holm-Šídák 
method as the default as recommended, α = 0.05) using Prism v6.0c (GraphPad). 
Transwell assays. Transwell assays were performed by plating 1 × 105 serum-starved and 
mytomicin C–treated (Sigma-Aldrich) MCF12A and NIH3T3 cells expressing PRKD1-tGFP, 
PRKD1(Glu710Asp)-tGFP and tGFP in low-serum growth medium (with 0.5% horse serum and 
0.5% FBS, respectively) into the upper chamber of a 24-well format Falcon Cell Culture Insert (8-
μm pore size; Corning); the lower compartment was filled with the corresponding complete growth 
medium. The assay was carried out for 18 h, and migratory cells on the lower side of the insert filter 
were fixed and stained with 1% crystal violet in 2% ethanol (Sigma-Aldrich). The entire well for 
each condition was photographed, and the various photos were merged using Adobe Photoshop 
(Photomerge tool). Experiments were performed in triplicate. Quantification of migrated cells was 
performed by automatic counting using the ImageJ software (v1.48b), and numbers were compared 
using an unpaired t test (GraphPad Prism v6.0c). A two-tailed P value of <0.05 was considered 
significant. 
Scratch wound healing assays. Serum-starved and mytomicin C–treated (Sigma-Aldrich) NIH3T3 
and MCF12A cells expressing PRKD1-tGFP, PRKD1(Glu710Asp)-tGFP and tGFP (control) were 
seeded at 90–95% confluency. After cell attachment, a p200 pipet tip was used to create a scratch in 
the cell monolayer. Representative phase-contrast images were taken at 0 h and 18 h after scratch 
wounding. Experiments were performed in triplicate. 
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